Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics

Core Insights - Quest Diagnostics will acquire select assets from Fresenius Medical Care's Spectra Laboratories, enhancing its portfolio in dialysis-related laboratory testing services [1][3] - The acquisition aims to improve operational efficiencies for Fresenius Medical Care and provide better services for patients at dialysis clinics [3][5] - The deal is expected to close in the second half of 2025, with a full transition of services anticipated by early 2026 [4] Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.1 million patients globally [7] - The company operates 3,732 dialysis clinics, providing treatments for around 308,000 patients worldwide [7] - Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the U.S., focusing on diagnostic insights to improve health outcomes [9] Industry Context - Chronic kidney disease affects about 35.5 million people in the U.S., representing 14% of the population, making it one of the most prevalent chronic diseases [6] - More than 800,000 individuals in the U.S. receive dialysis, which requires regular lab testing and water quality testing [6]